Annalisa Bramati
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Osimertinib in a patient with end-stage kidney disease not on hemodialysis.
Journal: Journal of nephrology
Published: February 20, 2024
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study.
Journal: Breast cancer research : BCR
Published: February 02, 2022
Author Correction: Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Journal: Scientific reports
Published: February 02, 2020
Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.
Journal: Scientific reports
Published: January 25, 2019
Localized morphea after breast implant for breast cancer: A case report.
Journal: Tumori
Published: May 02, 2018
The prognostic role of tumor size in early breast cancer in the era of molecular biology.
Journal: PloS one
Published: July 05, 2017
Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients.
Journal: British journal of cancer
Published: March 20, 2017
Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients.
Journal: Scientific reports
Published: June 10, 2014
Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin.
Journal: Future oncology (London, England)
Published: October 26, 2013
Efficacy of biological agents in metastatic triple-negative breast cancer.
Journal: Cancer treatment reviews
Published: August 06, 2013
Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases.
Journal: Journal of bone and mineral metabolism
Published: July 25, 2013
Last Updated: 09/26/2026